Technical guidance on the Introduction of HPV vaccines in European Union countries – an update
In January 2008, a panel of ECDC experts produced the Guidance for the introduction of HPV vaccines in EU countries. Since then, the European Union has come a long way: most countries have implemented national vaccination programmes for adolescent girls and a significant number have also introduced catch-up programmes for young women.
Expert opinion on the Introduction of HPV Vaccines in EU Countries
This guidance report lays down the scientific basis for the potential introduction of human papillomavirus (HPV) vaccines in order to help EU Member States to make policy choices
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Factsheet about human papillomavirus
Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union. Each year, there are around 33 000 cases of cervical cancer in the EU, and 15 000 deaths.
Public consultation on HPV vaccines guidance opens
This guidance covers the following areas in relation to HPV vaccination: efficacy of the nine-valent HPV vaccine, HPV vaccination in people living with HIV and HPV vaccination in males and the cost-effectiveness of extending the HPV vaccination programme to include males.
Evidence of efficacy of HPV vaccines in males
What is the evidence on the efficacy of the HPV vaccines in males?
Evidence of immunogenicity of HPV vaccines in males
What is the evidence on the immunogenicity of HPV vaccines in males?
Evidence of safety of HPV vaccines in males
What is the evidence on the safety of the HPV vaccines in males?